NEWPORT BEACH, Calif. — Vivera is proud to announce that it has received a patent for its groundbreaking Speech Fluency Evaluation and Feedback Monitoring Device from the US Patent and Trademark Office (USPTO). This milestone is a significant step towards improving the lives of patients with speech disfluencies like stuttering.
A speech fluency disorder is a communication disorder that can affect the smoothness, flow, and rate of speech. These disorders are characterized by disruptions in the natural rhythm and timing of speech, making it difficult for individuals to speak fluently and effortlessly. The most common fluency disorders are stuttering and cluttering, with stuttering alone affecting more than 70 million patients worldwide.
Often, patients who stutter experience stuttering events outside their healthcare provider’s office, making it more difficult to tailor and refine treatment recommendations and protocols. Vivera’s speech fluency device will allow for uninterrupted and continuous monitoring in various settings, ensuring that critical information and events aren’t missed. The device will be able to collect, aggregate, and analyze the data to provide the patient and the physician with a high-quality and actionable report.
“I am thrilled to be part of a team pushing the boundaries of medical technology and innovation,” said Mehdi Hatamian, Ph.D., Vivera’s Chief Scientific Advisor. “The speech fluency device is a prime example of our commitment to developing cutting-edge solutions that improve lives. With the granting of the patent, we are excited to bring this technology to the forefront of the speech assessment and feedback market and to continue expanding our technologies to make a meaningful impact on the healthcare industry.”
Vivera’s speech assessment and monitoring device may be used with a computing device, like a smartphone, to collect speech data or other relevant information. This data is then analyzed to detect speech events, such as instances of stuttering or other disruptions in fluency.
Based on the analysis, feedback is generated to help the speaker and their healthcare provider understand and improve their speech fluency. By utilizing artificial intelligence, machine learning, and advanced audio processing algorithms, the device aims to deliver actionable insights and personalized suggestions to users.
“The granting of this patent further validates the uniqueness and potential of our speech assessment and feedback technology,” said Paul Edalat, Chairman, Founder, and CEO of Vivera. “This technology has the potential to revolutionize the way clinicians approach speech therapy, and this achievement underscores our commitment to innovation and our dedication to making a positive difference in the lives of millions affected by communication challenges around the globe.”
With the patent in place, Vivera is now poised to accelerate the development and deployment of its speech assessment and feedback device. The Company is actively seeking partnerships with educational institutions, language schools, speech therapists, and other organizations that can benefit from this innovative technology.
As an advocate for putting patients first, Vivera is committed to transforming how we treat patients struggling with fluency challenges. The Company’s focus on research and development ensures that it remains at the forefront of innovative technology, providing unparalleled support and resources to individuals seeking to improve their speech fluency.
About
Vivera is an innovative, science-driven biopharma and medtech company located in Southern California. The Company has global exclusivity to license the patented and patent-pending TABMELT sublingual drug delivery system for pharmaceutical use and holds its own issued patents on ZICOH, an intelligent, dose-controlled electronic prescription dispensing device, MDZone, a portable telemedicine station and Conversall, its Speech Fluency Evaluation and Feedback Monitoring Device. With multiple divisions, including its technologies, biosciences, medical devices, and advanced diagnostics divisions, Vivera is vertically integrated with patented technology, manufacturing capabilities, and distribution for its products.
